What Omeros Corporation’s OncotoX-AML study reveals about mutation-agnostic AML therapies
Omeros Corporation advances OncotoX-AML after primate data. Explore what this means for AML therapy, risks ahead, and why clinicians are watching closely.
What GE HealthCare’s $35m BARDA expansion reveals about the future of trauma imaging
GE HealthCare expands its BARDA-backed artificial intelligence ultrasound program. Discover what this changes for trauma care and emergency preparedness.
How UNC Health’s Mevion deployment reflects a reset in proton therapy economics
UNC Health selects Mevion’s compact proton system. Discover what this means for proton therapy economics, workflows, and academic cancer care.
Instanosis secures FDA breakthrough status for xylazine urine test as overdose care faces new diagnostic gaps
Instanosis wins FDA breakthrough status for its xylazine urine test. Find out why this matters for overdose diagnostics and what challenges remain.
ViiV Healthcare’s Cabenuva and Dovato strategy looks like an ecosystem play as ultra long-acting candidates advance
ViiV Healthcare heads to CROI 2026 with ultra long-acting HIV data for VH4524184, VH4011499 and more. See what it changes next.
bioAffinity Technologies positions CyPath Lung as a confidence tool rather than a diagnostic replacement
Find out how bioAffinity Technologies’ CyPath Lung could reshape decision making for small lung nodules and what risks remain for adoption.
Why BIOEMTECH and NorthStar Medical Radioisotopes’ Actinium-225 agreement matters for preclinical alpha therapy development
BIOEMTECH secures Actinium-225 supply from NorthStar. Find out why isotope access now defines radiopharmaceutical development timelines.
Why Alcon’s TOTAL30 Multifocal for Astigmatism targets the toughest segment in contact lens care
Alcon has launched TOTAL30 Multifocal for Astigmatism in the U.S. Find out why this matters for presbyopia care and contact lens adoption.
Why Harmony Biosciences’ pitolisant approval changes the risk calculus in pediatric narcolepsy
FDA approval expands pitolisant into pediatric cataplexy. Explore what this changes for narcolepsy care, safety, and long-term strategy.
How the Prostate Cancer Foundation’s $6.3m bet on young investigators could shape the next decade of prostate cancer innovation
Discover why the Prostate Cancer Foundation’s $6.3 million investment in young researchers could shape the future of prostate cancer diagnostics and treatment.